Eli Lil­ly fi­nal­ly pub­lished its dis­as­trous EX­PE­DI­TION3 da­ta, a cost­ly les­son in re­think­ing Alzheimer's

Eli Lil­ly $LLY had hoped that EX­PE­DI­TION3 would prove to the world that amy­loid be­ta was the cause of Alzheimer’s and that solanezum­ab could bend the curve of cog­ni­tive de­cline back to pa­tients’ fa­vor — or at least for pa­tients with an ear­ly-stage, mild form of the dis­ease.

In­stead, the land­mark fail­ure — ac­knowl­edged well over a year ago — is rais­ing fresh ques­tions about whether in­ves­ti­ga­tors have been aim­ing at the wrong tar­get for more than a decade of flops and dis­as­trous fail­ures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA